

BIO-GENE – 2018 GOALS AND OBJECTIVES FOLLOWING SUCCESSFUL IPO

Key Objectives:

- Identify appropriate potential partners for product evaluation and development.
- Demonstrate the activity of our lead molecules Flavocide™ and Qcide™ in an increased number of market segments and target pests via laboratory studies and field trials.
- Implement the regulatory required toxicology and environmental safety studies required for product registration filings.
- Continue to develop improved production processes for Flavocide™ and Qcide™.
- Continue to evaluate and clarify the specifics around the unique mode of action of our lead molecules.
- Continue to generate data to support additional intellectual property creation and protection.
- Recruit leading scientific and industry experienced scientists to a Scientific Advisory Board.

Bio-Gene Technology Limited (ASX: BGT, “Bio-Gene” or “the Company”), an agtech development company enabling the next generation of novel insecticides to address insecticide resistance, provides the following update outlining its key goals and objectives for the 2018 calendar year following its successful IPO.

The key focus for Bio-Gene is to advance its technology in partnership with major agrichemical companies, similar to the existing collaboration with Virbac.

Engagement with international agrichemical companies has commenced to introduce them to the technology and to understand their processes and requirements for engaging in development partnerships. Based on the feedback of these initial discussions, Bio-Gene is continuing studies to demonstrate safety, efficacy, mode of action and manufacturing capability in order to provide the appropriate partnership enabling data packages. These programs are detailed in the table below.

The Company expects to be providing regular updates regarding these studies to the market from Q1 2018, as our results come to hand. In addition Bio-Gene anticipates providing an update on its collaboration discussions by early Q3 2018.

Key goals and objectives for the calendar year 2018 are shown below

Program	Objectives	Actions	Timelines
Efficacy Testing	Demonstrate the efficacy of lead molecules Flavocide™ and Qcide™ alone and/or in combination with other insecticide molecules against a number of pests relating to Public Health, Animal Health, Crop Protection, and Consumer use market segments to identify possible lead targets	Testing programs have commenced with a number of Contract Research Organisations (CROs) to perform the testing Complete initial field trials under Virbac collaboration	Ongoing as results come to hand throughout 2018 Virbac initial results expected 1H2018

Mode of Action	Clarify the specifics of the Mode of Action, with a view to apply for a new class of chemistry via IRAC	Ongoing studies with existing collaborators plus identification of groups with additional and specific expertise and assays	Filing of IRAC application Q4 2018
Intellectual property Development	Additional patent filings Data generation to support current and future patent filings	Generate data to support efficacy on resistant populations, synergistic effect of our molecules with other common insecticides, and new methods of manufacture	Ongoing throughout 2018
Safety data to support product registration packages	Continue formal toxicology and environmental safety studies with accredited third parties	Engage expert groups to perform necessary testing	Ongoing throughout 2018
Manufacturing Process Improvements	Improve on current manufacturing process to improve yield and reduce cost	Continue CSIRO collaboration. Engage with expert manufacturing scale-up collaborators	Improved process and initial scale up demonstration H2 2018
Identify and appoint experts to a Scientific Advisory Board (SAB)	Engage specialists in related fields to assess data and assist with next stage testing details	Approach known specialists and outline objectives for SAB.	First appointments completed by Q2 2018

For further information, please contact:

Bio-Gene Technology Limited:

Richard Jagger

CEO elect

P: 03 9628 4178

E: bgt.info@bio-gene.com.au

Roger McPherson

CFO & Company Secretary

P: 03 9628 4178

E: bgt.info@bio-gene.com.au

Media/investor relations:

Matthew Wright

NWR Communications

P: 0451 896 420

E: matt@nwrcommunications.com.au

About Bio-Gene Technology Ltd

Bio-Gene is an Australian AgTech development company enabling the next generation of novel insecticides to address the global problems of insecticide resistance and toxicity. Its novel platform technology is based on a naturally occurring class of chemicals known as beta-triketones.

Beta-triketone compounds have demonstrated insecticidal activity (e.g. kill or knock down insects) via a novel mode of action in testing performed to date. This platform may provide multiple potential new solutions for insecticide manufacturers in applications across animal health and crop protection, as well as in public health, and in consumer applications.

The Company's aim is to develop and commercialise a broad portfolio of targeted insect control and management solutions.